Trevi Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 7.82 million compared to USD 5.5 million a year ago. Basic loss per share from continuing operations was USD 0.08.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.67 USD | -8.56% | -9.27% | +104.48% |
05-07 | Transcript : Trevi Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024 | |
05-07 | Trevi Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+104.48% | 206M | |
+3.31% | 108B | |
+11.02% | 104B | |
+1.28% | 22.33B | |
-11.96% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-9.90% | 17.64B | |
+4.32% | 14.05B | |
+34.61% | 12.51B |
- Stock Market
- Equities
- TRVI Stock
- News Trevi Therapeutics, Inc.
- Trevi Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023